Skip to main content
Top
Published in: Infectious Agents and Cancer 2/2011

Open Access 01-12-2011 | Proceedings

Geographic and outcome variation among black men diagnosed with prostate cancer

Authors: Camille Ragin, Batsirai Mutetwa, Alison Attong-Rogers, Veronica Roach, Emanuela Taioli

Published in: Infectious Agents and Cancer | Special Issue 2/2011

Login to get access

Abstract

Background

Prostate cancer is the sixth leading cause of death from cancer among men worldwide. We have previously reported that prostate cancer survival rates for Caribbean-born males in the US was similar to survival rates of African-Americans and was higher than their counterparts diagnosed in the Caribbean. However, it is not clear whether differences in mortality could be attributed to differences in treatment.

Methods

This current analysis seeks to further explore reasons for the geographic variation of prostate cancer survival for Caribbean-born men. This analysis included 2,554 Black newly diagnosed prostate cancer cases (960 cases diagnosed in the US and 1,594 cases diagnosed in the Caribbean). Clinical data were extracted from the cancer registry and clinical charts.

Results

There were noted differences in the pattern of treatment for each place of birth category when stratified according to disease stage at diagnosis. Among the patients diagnosed with early-intermediate disease (stage I-III) the majority of US-born Brooklyn men were treated with surgery only (31%) and a similar pattern was observed for Caribbean-born Brooklyn men (35%). In contrast, the majority of Caribbean-born Trinidad & Tobago men were treated with hormone therapy (31%).
Caribbean-born men diagnosed in the Caribbean had a significantly higher risk of death from prostate cancer (Adjusted Hazard [AdjHR]: 3.7, 95% Confidence Interval [CI]: 2.8-5.0) when compared with the risk of death for Caribbean-born males diagnosed in the US. This observation was consistent for each treatment group with the exception of the cases treated with hormone therapy only. For these cases, there was no difference in the risk of death between Caribbean-born males diagnosed in the Caribbean (AdjHR: 1.4, 95% CI: 0.8-2.6) compared to Caribbean-born males diagnosed in the US.

Conclusions

In addition to difference in access and utilization of screening, differences in treatment strategy may also be a strong predictor of outcome for Caribbean-born males diagnosed with prostate cancer. Further studies are needed to confirm these findings. In addition, other environmental factors related to survival that was not considered in this analysis also need to be investigated.
Literature
1.
go back to reference Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. 2010, Lyon, France: International Agency for Research on Cancer Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. 2010, Lyon, France: International Agency for Research on Cancer
2.
go back to reference Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H: SEER Cancer Statistics Review, 1975-2007. 2010, Bethesda, MD: National Cancer Institute Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H: SEER Cancer Statistics Review, 1975-2007. 2010, Bethesda, MD: National Cancer Institute
3.
go back to reference Mutetwa B, Taioli E, Attong-Rogers A, Layne P, Roach V, Ragin C: Prostate cancer characteristics and survival in males of African Ancestry according to place of birth: Data from Brooklyn - New York, Guyana, Tobago and Trinidad. Prostate. 2010, 70: 1102-1109. 10.1002/pros.21144.PubMedCentralCrossRefPubMed Mutetwa B, Taioli E, Attong-Rogers A, Layne P, Roach V, Ragin C: Prostate cancer characteristics and survival in males of African Ancestry according to place of birth: Data from Brooklyn - New York, Guyana, Tobago and Trinidad. Prostate. 2010, 70: 1102-1109. 10.1002/pros.21144.PubMedCentralCrossRefPubMed
4.
go back to reference Coleman MP, Quaresma M, Berrino F, Lutz JM, de Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T: Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008, 9: 730-756. 10.1016/S1470-2045(08)70179-7.CrossRefPubMed Coleman MP, Quaresma M, Berrino F, Lutz JM, de Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T: Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008, 9: 730-756. 10.1016/S1470-2045(08)70179-7.CrossRefPubMed
5.
go back to reference Bunker CH, Patrick AL, Konety BR, Dhir R, Brufsky AM, Vivas CA, Becich MJ, Trump DL, Kuller LH: High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiol Biomarkers Prev. 2002, 11: 726-729.PubMed Bunker CH, Patrick AL, Konety BR, Dhir R, Brufsky AM, Vivas CA, Becich MJ, Trump DL, Kuller LH: High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiol Biomarkers Prev. 2002, 11: 726-729.PubMed
Metadata
Title
Geographic and outcome variation among black men diagnosed with prostate cancer
Authors
Camille Ragin
Batsirai Mutetwa
Alison Attong-Rogers
Veronica Roach
Emanuela Taioli
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Infectious Agents and Cancer / Issue Special Issue 2/2011
Electronic ISSN: 1750-9378
DOI
https://doi.org/10.1186/1750-9378-6-S2-S2

Other articles of this Special Issue 2/2011

Infectious Agents and Cancer 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine